Overview
HCA Q3 revenue grows 9.6% to $19.161 bln, beating analyst expectations
Net income for Q3 rises 29.4% to $1.643 bln
Company raises 2025 guidance for revenue, net income, and adjusted EBITDA
Outlook
HCA Healthcare raises 2025 revenue guidance to $75 bln-$76.5 bln
Company increases 2025 net income forecast to $6.495 bln-$6.715 bln
HCA Healthcare expects 2025 EPS of $27.00-$28.00 per diluted share
Result Drivers
ADMISSIONS GROWTH - Same facility admissions increased 2.1%, contributing to revenue growth
REVENUE PER ADMISSION - Same facility revenue per equivalent admission increased 6.6%, boosting overall revenue
WEATHER IMPACT - Absence of hurricane-related disruptions in 2025 compared to 2024 supported results
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$19.16 bln
$18.56 bln (18 Analysts)
Q3 ADJUSTED EPS
$6.96
Q3 EPS
$6.96
Q3 Net Income
$1.90 bln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for HCA Healthcare Inc is $430.00, about 2.4% below its October 23 closing price of $440.16
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago
Press Release: ID:nBw4gvgQXa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)